| Product Unit Size | Cost | Quantity | Stock |
|---|
AT-7519 is an ATP competitive CDK inhibitor showing activity against CDK1, 2, 4, 6, and 9. It causes cell cycle arrest followed by apoptosis in human tumor cells and inhibits tumor growth in human tumor xenograft models. It also induces apoptosis in multiple myeloma cells via GSK-3β activation.
| Cas No. | 844442-38-2 |
|---|---|
| Purity | ≥98% |
| Formula | C16H17Cl2N5O2 |
| Formula Wt. | 382.25 |
| Chemical Name | n-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxamide |
| IUPAC Name | 4-[(2,6-Dichlorobenzoyl)amino]-N-(4-piperidinyl)-1H-pyrazole-3-carboxamide |
| Synonym | AT7519; 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Santo L., Vallet S., et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition. Oncogene. 29:2325-2336 (2010). PMID: 20101221.
Squires M., Feltell R., et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Molecular Cancer Therapeutics. 8(2):324-332 (2009). PMID: 19174555.